Google DeepMind has announced a major breakthrough in predicting how proteins interact with each other and with drug molecules, building on its earlier AlphaFold achievements. The new model, called AlphaFold-Interact, can accurately predict the binding affinity and structural dynamics of protein-protein and protein-drug complexes with unprecedented accuracy.
Pharmaceutical companies are already licensing the technology, with Eli Lilly and Novartis signing multi-year agreements to integrate AlphaFold-Interact into their drug discovery pipelines. DeepMind estimates the tool could reduce early-stage drug development timelines by 40% and significantly lower the cost of identifying viable therapeutic candidates.
The research community has hailed the achievement as a transformative moment for computational biology, though experts caution that laboratory validation remains essential before AI-predicted interactions can advance to clinical trials.
